Business Context and Reporting Period
Company: Neogen Corporation
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter and six months ended November 30, 2009
Business Overview: Neogen operates two reportable segments: Food Safety (diagnostic test kits for toxins, bacteria, allergens) and Animal Safety (veterinary instruments, rodenticides, disinfectants). The company serves food producers, processors, and veterinarians globally.
Key Financial Metrics
| Metric | Three Months Ended Nov 30, 2009 | Six Months Ended Nov 30, 2009 |
|---|---|---|
| Net Sales | $35.25 million | $67.60 million |
| Gross Margin | $18.52 million (52.5%) | $35.79 million (52.9%) |
| Operating Income | $7.23 million (20.5%) | $14.17 million (21.0%) |
| Net Income | $4.61 million | $9.01 million |
| Diluted EPS | $0.20 | $0.39 |
| Cash from Operations (6mo) | $16.50 million | |
| Cash and Equivalents (Nov 30, 2009) | $32.45 million | |
| Long-Term Debt | $0 (No amounts drawn on $10M line of credit) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 13% in the quarter and 13% year-to-date compared to the prior year. Food Safety sales grew 20% (quarter) and 16% (YTD), while Animal Safety grew 6% (quarter) and 9% (YTD).
- Margin Expansion: Gross margins improved from 51.7% to 52.5% in the quarter and from 51.6% to 52.9% YTD, driven by a favorable product mix shift toward higher-margin diagnostic products.
- Operating Efficiency: Operating margins rose to 20.5% (quarter) and 21.0% (YTD) due to gross margin improvements and cost controls. Sales and marketing expenses as a percentage of revenue decreased.
- Acquisition Impact: Growth was bolstered by the May 2009 acquisition of International Diagnostics Systems (IDS) and the June 2008 acquisition of a disinfectant business from DuPont. Organic growth was 12% in the quarter and 11% YTD.
- Cash Flow: Net cash provided by operating activities surged to $16.50 million for the six-month period, compared to $5.12 million in the prior year, aided by inventory reduction efforts.
Outlook, Risks, and Unusual Items
- Guidance: Management explicitly states it does not provide forecasts of future performance. Historical results are not necessarily indicative of future results.
- Subsequent Event: On December 1, 2009, Neogen acquired the Biokits food safety business of Gen-Probe for approximately $6.5 million in cash plus assumption of $175,000 in trade payables.
- Stock Split: A 3-for-2 stock split was declared effective December 15, 2009. All share and per-share amounts in the filing reflect this split retroactively.
- Risks: Key risks include competition, dependence on key employees, weather impacts on agriculture, integration of acquisitions, and foreign exchange rate fluctuations (exposure to British Pound and Euro).
- Contingencies: The company has an estimated liability of $916,000 for environmental remediation at its Randolph, Wisconsin facility. No material legal proceedings are expected to impact future results.
Investor Verification Checklist
- Acquisition Integration: Verify the financial contribution and integration status of the IDS and Gen-Probe (Biokits) acquisitions.
- Organic Growth Sustainability: Confirm if the 11-12% organic growth rate is sustainable without further M&A activity.
- Capital Expenditures: Monitor the impact of the new lease-purchasing financing alternative for Soleris capital equipment on future revenue recognition.
- Foreign Exchange Exposure: Assess the impact of currency fluctuations on the 40% of sales generated internationally.
- Stock Split Impact: Ensure all historical comparisons account for the 3-for-2 stock split effective December 15, 2009.